Drugs / Tomligisiran
last change Nov 2024 re-read 2 minutes ago

Tomligisiran

Developed for
chronic hepatitis B virus infection
Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT06537414 Nov 2024 → May 2027 expected chronic hepatitis B virus infection GlaxoSmithKline Active not recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Tomligisiran ClinicalTrials.gov intervention name — accepted as the source's own label NCT06537414